Luisa Costanzo

Luisa Costanzo

Auto-generated profile, based on publicly available information

Luisa Costanzo

Geriatric Unit, Campus Bio-Medico University, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
Claudio PedoneClaudio Pedone
Claudio Pedone
FRFrancesca Flavia Rossi
Francesca Flavia Rossi
ACAnnagrazia Cecere
Annagrazia Cecere
LCLuisa Costanzo
Luisa Costanzo
Raffaele Antonelli IncalziRaffaele Antonelli Incalzi
Raffaele Antonelli Incalzi

18 June 2020 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
LCLuisa Costanzo
Luisa Costanzo
AVAntonio De Vincentis
Antonio De Vincentis
AIAngelo Di Iorio
Angelo Di Iorio
SBStefania Bandinelli
Stefania Bandinelli
LFLuigi Ferrucci
Luigi Ferrucci
CPClaudio Pedone
Claudio Pedone
Background: A universal definition of sarcopenia is still lacking. Since the European criteria have been recently revised, we aimed at studying prevalence of low muscle strength (LMS) and low muscle mass (LMM), as defined according to the European Working Group of Sarcopenia in Older People (EWGSOP) 2 and 1 definitions, and their individual contribution toward mortality and incident mobility disability in a cohort of community-dwelling older people. Methods: Longitudinal analysis of 535 participants of the InCHIANTI study. LMS and LMM were defined according to the criteria indicated in the EWGSOP2 and 1. Cox and log-binomial regressions were used to examine association with mortality and 3-year mobility disability (inability to walk 400 m). Results: We observed a lower prevalence of the combination LMM/LMS according to EWGSOP2 compared to EWGSOP1 (3.2% vs 6.2%). Using the new criteria, all sarcopenia components were associated with mortality, although the hazard ratio [HR] for the group LMM/LMS was no longer significant after adjustment for confounders (LMM: HR 2.69, 95% confidence interval [CI] 1.04–6.94; LMS: HR 3.18, 95% CI 1.44–7.01; LMM/LMS: HR 2.95, 95% CI 0.86–10.16). Using EWGSOP1, LMS alone was independently associated with mortality (HR 4.43, 95% CI 1.85–10.57). None of the sarcopenia components conferred a higher risk of mobility disability. Conclusions: The EWGSOP2 algorithm leads to a reduction in the estimated prevalence of sarcopenia defined as combination of LMM/LMS. The finding that, independent of the adopted criteria, people with LMS and normal mass have a higher mortality risk compared to robust individuals, confirms that evaluation of muscle strength has a central role for prognosis evaluation.


13 August 2015 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
Claudio PedoneClaudio Pedone
Claudio Pedone
LCLuisa Costanzo
Luisa Costanzo
Matteo  CesariMatteo Cesari
Matteo Cesari
SBStefania Bandinelli
Stefania Bandinelli
LFLuigi Ferrucci
Luigi Ferrucci
RIRaffaele Antonelli Incalzi
Raffaele Antonelli Incalzi
Background. The frailty phenotype (FP) proposed by Fried and colleagues (Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156.) requires the administration of performance tests (gait speed, handgrip strength) not always feasible in routine clinical practice. Furthermore, the discriminative capacity of the instrument has been rarely investigated. Aim of this study was to evaluate the discriminative capacity of the FP and compare it with a modified version including only anamnestic information. Methods. Data are from 890 participants of the InCHIANTI study without impairment in activities of daily living (ADL) at baseline (mean age 74 years, women 55%). Frailty was defined by (a) the presence of ≥3 criteria of the FP, and (b) having ≥2 criteria of an anamnestic FP (AFP), not including gait speed and handgrip strength. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were used to evaluate the discriminative capacity of both definitions for incident disability (ie, loss of at least one ADL), incidence of “accelerated” disability (loss of >2 ADL) over a 6-year follow-up, and 5-years mortality. Results. FP and AFP yielded a frailty prevalence of 6.4% and 6.5%, respectively; only 32 patients were considered frail by both indices (kappa: .53). For incident disability, FP showed sensitivity = .194, specificity = .963, PPV = .400, and NPV = .903. Similarly, AFP had sensitivity = .129, specificity = .949, PPV = .245, and NPV = .894. Consistent results were found for accelerated disability and mortality. Conclusions. In our sample, both FP and AFP showed low sensitivity in identifying older people who would die or develop disability, but they could well discriminate people who would not experience adverse outcomes.

21 March 2016 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
LCLuisa Costanzo
Luisa Costanzo
Claudio PedoneClaudio Pedone
Claudio Pedone
FBFabrizio Battistoni
Fabrizio Battistoni
DCDomenica Chiurco
Domenica Chiurco
SSSimona Santangelo
Simona Santangelo
RARaffaele Antonelli-Incalzi
Raffaele Antonelli-Incalzi

4 October 2013 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
LCLuisa Costanzo
Luisa Costanzo
SSSimone Scarlata
Simone Scarlata
Giuseppe PerroneGiuseppe Perrone
Giuseppe Perrone
LRLuigi Rossi
Luigi Rossi
APAnselmo Papa
Anselmo Papa
STSilverio Tomao
Silverio Tomao